Stock listing
NASDAQ:ALZN Alzamend Neuro, Inc. Stock
Home listing (NASDAQ) of Alzamend Neuro, Inc.
Follow Alzamend Neuro, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ALZN
$0.776 USD -0.244 (-23.9%)
Close on Nov 20, 2026
- Day range
- $0.754 – $1.000 USDNov 20, 2026
- Volume
- 93,200 sharesNov 20, 2026
- Market cap
- $3.74M USDAt the close on Nov 20, 2026 · price × 4.83M shares outstanding
- 52-week range
- $0.754 – $2.535 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $126,529 USDMedian day 37,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ALZN · Home | $0.776 USD | -0.244 (-23.9%) | 93,200 | $1.000 | $1.000 | $0.754 | $1.020 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ALZN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.776 | -0.244 | -23.9% | $1.000 | $1.000 | $0.754 | 93,200 | |
| $1.020 | -0.020 | -1.9% | $1.020 | $1.205 | $1.000 | 37,100 | |
| $1.040 | -0.090 | -8.0% | $1.120 | $1.130 | $1.010 | 36,300 | |
| $1.130 | -0.050 | -4.2% | $1.180 | $1.180 | $1.117 | 20,700 | |
| $1.180 | -0.060 | -4.8% | $1.230 | $1.298 | $1.110 | 49,500 | |
| $1.240 | -0.060 | -4.6% | $1.340 | $1.380 | $1.227 | 38,800 | |
| $1.300 | -0.010 | -0.8% | $1.290 | $1.371 | $1.250 | 23,700 | |
| $1.310 | -0.040 | -3.0% | $1.370 | $1.445 | $1.290 | 13,400 | |
| $1.350 | -0.070 | -4.9% | $1.390 | $1.450 | $1.330 | 15,900 | |
| $1.420 | +0.010 | +0.7% | $1.440 | $1.520 | $1.330 | 61,500 | |
| $1.410 | -0.140 | -9.0% | $1.660 | $1.660 | $1.341 | 38,100 | |
| $1.550 | +0.020 | +1.3% | $1.600 | $1.620 | $1.507 | 76,000 | |
| $1.530 | +0.070 | +4.8% | $1.535 | $1.620 | $1.480 | 72,100 | |
| $1.460 | +0.210 | +16.8% | $1.240 | $1.526 | $1.240 | 240,500 | |
| $1.250 | +0.040 | +3.3% | $1.320 | $1.330 | $1.210 | 37,100 | |
| $1.210 | -0.010 | -0.8% | $1.290 | $1.329 | $1.210 | 25,000 | |
| $1.220 | +0.030 | +2.5% | $1.365 | $1.365 | $1.200 | 15,800 | |
| $1.190 | +0.060 | +5.3% | $1.155 | $1.230 | $1.120 | 21,400 | |
| $1.130 | -0.010 | -0.9% | $1.170 | $1.249 | $1.110 | 8,800 | |
| $1.140 | +0.010 | +0.9% | $1.100 | $1.155 | $1.100 | 25,700 | |
| $1.130 | +0.010 | +0.9% | $1.110 | $1.190 | $1.100 | 29,100 | |
| $1.120 | -0.130 | -10.4% | $1.250 | $1.290 | $1.120 | 15,300 | |
| $1.250 | -0.050 | -3.8% | $1.290 | $1.390 | $1.250 | 10,500 | |
| $1.300 | -0.030 | -2.3% | $1.300 | $1.330 | $1.280 | 10,900 | |
| $1.330 | +0.030 | +2.3% | $1.340 | $1.345 | $1.310 | 6,500 | |
| $1.300 | +0.020 | +1.6% | $1.290 | $1.340 | $1.250 | 15,900 | |
| $1.280 | -0.070 | -5.2% | $1.320 | $1.335 | $1.280 | 15,000 | |
| $1.350 | 0.000 | 0.0% | $1.310 | $1.396 | $1.310 | 23,200 | |
| $1.350 | +0.040 | +3.1% | $1.430 | $1.430 | $1.300 | 18,000 | |
| $1.310 | -0.030 | -2.2% | $1.400 | $1.429 | $1.310 | 17,000 | |
| $1.340 | 0.000 | 0.0% | $1.430 | $1.430 | $1.340 | 13,300 | |
| $1.340 | -0.030 | -2.2% | $1.320 | $1.350 | $1.220 | 7,000 | |
| $1.370 | 0.000 | 0.0% | $1.370 | $1.420 | $1.340 | 18,800 | |
| $1.370 | -0.040 | -2.8% | $1.435 | $1.435 | $1.343 | 32,100 | |
| $1.410 | +0.040 | +2.9% | $1.380 | $1.480 | $1.375 | 25,400 | |
| $1.370 | +0.055 | +4.2% | $1.410 | $1.480 | $1.200 | 236,400 | |
| $1.315 | -0.415 | -24.0% | $1.720 | $1.720 | $1.260 | 150,600 | |
| $1.730 | -0.090 | -4.9% | $1.840 | $1.840 | $1.730 | 21,700 | |
| $1.820 | +0.090 | +5.2% | $1.745 | $1.850 | $1.740 | 49,500 | |
| $1.730 | -0.100 | -5.5% | $1.800 | $1.920 | $1.730 | 83,800 | |
| $1.830 | +0.010 | +0.5% | $1.900 | $1.900 | $1.764 | 23,300 | |
| $1.820 | -0.120 | -6.2% | $1.900 | $1.930 | $1.820 | 150,500 | |
| $1.940 | 0.000 | 0.0% | $1.930 | $1.950 | $1.930 | 45,800 | |
| $1.940 | 0.000 | 0.0% | $1.930 | $1.940 | $1.900 | 91,200 | |
| $1.940 | +0.050 | +2.6% | $1.890 | $1.940 | $1.870 | 206,700 | |
| $1.890 | +0.050 | +2.7% | $1.840 | $1.890 | $1.810 | 240,700 | |
| $1.840 | +0.010 | +0.5% | $1.830 | $1.840 | $1.820 | 42,700 | |
| $1.830 | +0.050 | +2.8% | $1.790 | $1.850 | $1.790 | 167,600 | |
| $1.780 | +0.030 | +1.7% | $1.750 | $1.790 | $1.725 | 230,000 | |
| $1.750 | +0.030 | +1.7% | $1.720 | $1.760 | $1.709 | 69,100 | |
| $1.720 | +0.020 | +1.2% | $1.670 | $1.760 | $1.590 | 393,600 | |
| $1.700 | +0.020 | +1.2% | $1.670 | $1.700 | $1.576 | 8,800 | |
| $1.680 | 0.000 | 0.0% | $1.690 | $1.730 | $1.645 | 29,600 | |
| $1.680 | +0.020 | +1.2% | $1.660 | $1.717 | $1.620 | 31,200 | |
| $1.660 | -0.040 | -2.4% | $1.700 | $1.730 | $1.650 | 63,200 | |
| $1.700 | 0.000 | 0.0% | $1.650 | $1.720 | $1.650 | 128,200 | |
| $1.700 | +0.063 | +3.8% | $1.650 | $1.700 | $1.565 | 100,700 | |
| $1.637 | +0.037 | +2.3% | $1.615 | $1.680 | $1.615 | 23,300 | |
| $1.600 | -0.060 | -3.6% | $1.655 | $1.655 | $1.510 | 37,700 | |
| $1.660 | -0.005 | -0.3% | $1.640 | $1.720 | $1.640 | 242,100 | |
| $1.665 | -0.005 | -0.3% | $1.670 | $1.670 | $1.650 | 39,700 | |
| $1.670 | +0.070 | +4.4% | $1.590 | $1.670 | $1.550 | 125,300 | |
| $1.600 | +0.050 | +3.2% | $1.530 | $1.650 | $1.501 | 122,000 | |
| $1.550 | -0.010 | -0.6% | $1.510 | $1.580 | $1.410 | 133,800 | |
| $1.560 | -0.070 | -4.3% | $1.570 | $1.598 | $1.490 | 242,700 | |
| $1.630 | +0.110 | +7.2% | $1.560 | $1.670 | $1.532 | 486,200 |
Splits
3 splits since 2023 · NASDAQ:ALZN · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-9 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-15 | Consolidation |
- Ticker
- NASDAQ:ALZN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Aug 20, 2026
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 29 slides
Latest news
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
Aug 20, 2026
Closed $1.63 (+7.2%) on Aug 20, 2026
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
Aug 4, 2026
Closed $1.45 (+8.2%) on Aug 4, 2026
Annual Report for Fiscal Year Ending April 30, 2026 (Form 10-K)
Jul 22, 2026
Closed $1.26 (-6.7%) on Jul 23, 2026
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Apr 7, 2026
Closed $0.927 (-2.4%) on Apr 7, 2026
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
Mar 26, 2026
Closed $1.50 (-22.3%) on Mar 26, 2026
Alzamend Neuro, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 6 in the last 12 months · 72 in all · newest Aug 20, 2026 · oldest 2021
- Decks
- 12 decks · latest November 2026
Where Alzamend Neuro, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ALZN · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ALZN | BOATS | United States | USD |
Valuation
Price/book 0.7× against a median of 0.8×: 4th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Jul 31, 2026 · price Nov 20, 2026
- Enterprise value
- −$3.85M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 2.00
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Alzamend Neuro, Inc. · NASDAQ:ALZN | US$3.74M | −US$3.85M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 2.00 |
| Processa Pharmaceuticals, Inc. · NASDAQ:PCSA | US$4.37M | −US$175.8M | n/a | n/a | n/a | n/a | n/a | n/a | 1.60 |
| AdAlta Ltd. · ASX:1AD | US$4.25M | US$3.40M | n/a | n/a | n/a | 17.4× | n/a | 0.0× | n/a |
| Percheron Therapeutics Limited · ASX:PER | US$3.94M | US$1.27M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | n/a |
| Lantern Pharma Inc. · NASDAQ:LTRN | US$3.89M | −US$3.69M | n/a | n/a | n/a | 2.8× | n/a | 0.0× | 2.80 |
| Silo Pharma, Inc. · NASDAQ:SILO | US$3.77M | −US$4.28M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.23 |
| Biotron Limited · ASX:BIT | US$3.69M | US$2.66M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| Reviva Pharmaceuticals Holdings, Inc. · NASDAQ:RVPH | US$3.68M | −US$13.77M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.57 |
| Liminatus Pharma, Inc. · NASDAQ:LIMN | US$3.37M | US$1.80M | n/a | n/a | n/a | 11.2× | n/a | 4.8× | 0.94 |
| Xenetic Biosciences, Inc. · NASDAQ:XBIO | US$3.28M | −US$2.53M | n/a | −0.8× | n/a | 0.7× | −123.7% | 0.0× | 1.46 |
| Aprea Therapeutics, Inc. · NASDAQ:APRE | US$3.25M | −US$34.60M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.73 |
| Median of the others | US$3.73M | −US$3.11M | −0.8× | 0.8× | −123.7% | 0.0× | 1.46 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- Price target
- 26.00 USD · Analysts' mean
- EPS, year to Apr 2027
- -1.05 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Stephan Jackman | Chief Executive Officer and Director |
| William B. Horne | Chairman of Alzamend, Chief Executive Officer of Ault Alliance, Inc. |
| David J. Katzoff | Chief Financial Officer |
| Mark Gustafson C.P.A. | Chief Financial Officer of PharmaKure Limited |
| Henry C.W. Nisser | Executive Vice President, General Counsel and Director |
| Kenneth S. Cragun | Senior Vice President of Finance |
| Milton C Ault | Founder and Vice Chairman of Alzamend |
Board
| Director | Role |
|---|---|
| William B. Horne | Chairman of Alzamend, Chief Executive Officer of Ault Alliance, Inc. |
| Henry C.W. Nisser | Executive Vice President, General Counsel and Director |
| Milton C Ault | Founder and Vice Chairman of Alzamend |
| Stephan Jackman | Chief Executive Officer and Director |
Events
- Next results
- Dec 8, 2026 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q1 2027 | Sep 10, 2026 · After close | +1.2% |
| Q4 2026 | Jul 22, 2026 · After close | −6.7% |
| Q3 2026 | Mar 11, 2026 · After close | −4.1% |
| Q2 2026 | Dec 9, 2025 · After close | −0.5% |
| Q1 2026 | Sep 10, 2025 · After close | +2.1% |
| Q4 2025 | Jul 22, 2025 · After close | −5.9% |
| Q3 2025 | Mar 10, 2025 · After close | −1.6% |
| Q2 2025 | Dec 11, 2024 · After close | −0.8% |
| Q1 2025 | Sep 11, 2024 · After close | −0.5% |
| Q4 2024 | Jul 27, 2024 · After close | +4.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2024 | Mar 25, 2024 · After close | −1.5% |
| Q2 2024 | Dec 15, 2023 · After close | 0.0% |
| Q1 2024 | Sep 13, 2023 · After close | −1.3% |
| Q4 2023 | Jul 27, 2023 · After close | +0.8% |
| Q3 2023 | Mar 15, 2023 · After close | −4.8% |
| Q2 2023 | Dec 12, 2022 · After close | −0.9% |
| Q1 2023 | Sep 13, 2022 · After close | +6.5% |
| Q4 2022 | Jul 19, 2022 · After close | +2.0% |
| Q3 2022 | Mar 15, 2022 · After close | +8.9% |
| Q2 2022 | Dec 13, 2021 · After close | +28.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 29 slides | November 2026 |
| ISMRM Workshop Advances in X-Nuclei MR 2026 | Conference | 17 slides | Sep 29, 2026 |
| Investor Presentation (July 2026) | Investor deck | 29 slides | July 2026 |
| Investor Presentation (May 2024) | Investor deck | 30 slides | May 15, 2024 |
| Investor Presentation (April 2023) | Investor deck | 28 slides | Apr 25, 2023 |
| Investor Presentation (January 2023) | Investor deck | 27 slides | Jan 20, 2023 |
| Investor Presentation (November 2022) | Investor deck | 27 slides | Nov 16, 2022 |
| Investor Presentation (August 2022) | Investor deck | 27 slides | Aug 15, 2022 |
| Investor Presentation (June 2022) | Investor deck | 27 slides | Jun 6, 2022 |
| Investor Presentation (April 2022) | Investor deck | 24 slides | Apr 18, 2022 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| IPO Roadshow (June 2021) | IPO roadshow | 20 slides | Jun 7, 2021 |
| IPO Roadshow (May 2021) | IPO roadshow | 21 slides | May 28, 2021 |
Financings
| Raise | Date |
|---|---|
| Series D Convertible Preferred Stock Tranche closed: US$7.5M raised · US$1,000 a share Buyers: Ault Lending, LLC (agreed to purchase up to 25,000 Preferred Shares for $25,000,000; purchased 7,500 Preferred Shares for $7,500,000 at the initial closing) Use of proceeds: General working capital and corporate purposes, including furthering its clinical trials | Aug 4, 2026 |
| Private placement of series C Convertible Preferred Stock and warrants Closed: private placement Use of proceeds: To support the five Phase II clinical trials of AL001 Lithium in Brain studies at Massachusetts General Hospital | Jun 16, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$5.00 a share on Jun 14, 2021.
- Price
- US$5.00 a share
- Shares offered
- 2,500,000 shares of common stock
- Offering size
- US$12.5 million
- Underwriters' option
- Up to 375,000 more shares
- Listing
- ALZN on the Nasdaq Capital Market
- Underwriter
- Spartan Capital Securities, LLC
- Shares delivered
- On or about Jun 17, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 29, 2020 |
| Filed publicly | May 10, 2021 |
| Amended 4 times | Newest Jun 11, 2021 |
| Shares registered with an exchange | Jun 11, 2021 |
| Declared effective by the SEC | Jun 14, 2021 |
| Final prospectus, with the price | Jun 15, 2021 |
Filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jun 15, 2021 |
| 424B4 · Prospectus | Jun 15, 2021 |
| EFFECT · Notice that a registration is effective | Jun 14, 2021 |
| CORRESP · Letter to the SEC | Jun 14, 2021 |
| CERT · Exchange's certificate of listing | Jun 14, 2021 |
| S-1/A · Registration statement, amended | Jun 11, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 11, 2021 |
| CORRESP · Letter to the SEC | Jun 10, 2021 |
| CORRESP · Letter to the SEC | Jun 10, 2021 |
| CORRESP · Letter to the SEC | Jun 10, 2021 |
All 32 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jun 9, 2021 |
| FWP · Free writing prospectus | Jun 7, 2021 |
| S-1/A · Registration statement, amended | Jun 7, 2021 |
| CORRESP · Letter to the SEC | Jun 7, 2021 |
| UPLOAD · Letter from the SEC | Jun 4, 2021 |
| CORRESP · Letter to the SEC | Jun 3, 2021 |
| S-1/A · Registration statement, amended | Jun 3, 2021 |
| UPLOAD · Letter from the SEC | Jun 2, 2021 |
| FWP · Free writing prospectus | May 28, 2021 |
| CORRESP · Letter to the SEC | May 28, 2021 |
| CORRESP · Letter to the SEC | May 27, 2021 |
| CORRESP · Letter to the SEC | May 25, 2021 |
| S-1/A · Registration statement, amended | May 25, 2021 |
| UPLOAD · Letter from the SEC | May 20, 2021 |
| CORRESP · Letter to the SEC | May 10, 2021 |
| S-1 · Registration statement | May 10, 2021 |
| UPLOAD · Letter from the SEC | Apr 20, 2021 |
| DRSLTR · Letter to the SEC with a draft | Apr 2, 2021 |
| DRS/A · Draft registration statement, amended | Apr 2, 2021 |
| UPLOAD · Letter from the SEC | Jan 25, 2021 |
| DRSLTR · Letter to the SEC with a draft | Dec 29, 2020 |
| DRS · Draft registration statement | Dec 29, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 15, 2021
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Research and development | 3.63M | 1.41M | 6.46M | 7.45M | 5.20M | 1.31M | 1.07M |
| Operating income | -8.77M | -4.50M | -9.94M | -14.9M | -12.3M | -4.95M | -4.42M |
| Depreciation and amortization | 110.7K | 50.7K | 50.7K | 23.1K | 3.55K | ||
| EBITDA | -8.66M | -4.45M | -9.89M | -14.8M | -12.3M | ||
| Interest expense | 6.62K | 18.0K | 10.1K | 7.70K | 46.5K | 142.4K | |
| Income before tax | -8.77M | -4.51M | -9.95M | -14.9M | -12.4M | -5.05M | -4.41M |
| Net income | -8.77M | -4.51M | -9.95M | -14.9M | -12.4M | -5.05M | -4.41M |
| Earnings per share, basic | -2.63 | -11.32 | -132.33 | -22.89 | -0.14 | -0.07 | -0.06 |
| Earnings per share, diluted | -2.63 | -11.32 | -132.33 | -22.89 | -0.14 | -0.07 | -0.06 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 710.7K | 3.95M | 376.0K | 5.14M | 14.1M | 1.93M | 90.3K |
| Current assets | 1.76M | 4.18M | 455.2K | 5.84M | 14.4M | 2.91M | 1.81M |
| Property, plant and equipment | 314.9K | 425.6K | 176.3K | 79.8K | 102.9K | ||
| Total assets | 2.08M | 4.60M | 631.6K | 5.92M | 14.5M | 2.91M | 1.81M |
| Accounts payable | 2.93M | 2.87M | 1.16M | 503.6K | 929.6K | ||
| Current liabilities | 2.87M | 1.16M | 899.6K | 992.3K | |||
| Total liabilities | 1.35M | 634.8K | 3.23M | 2.87M | 1.16M | 899.6K | |
| Shareholders' equity | 733.2K | 3.97M | -2.59M | 3.05M | 13.4M | 2.01M | 821.7K |
| Shares outstanding | 4.26M | 778.7K | 76.4K | 646.3K | 95.5M | 67.4M | 64.8M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -8.07M | -6.57M | -8.27M | -8.92M | -6.61M | -2.71M | -2.35M |
| Cash from investing | -300.0K | -147.2K | -106.5K | 100.9K | 105.0K | ||
| Cash from financing | 4.83M | 10.4M | 3.65M | 200 | 18.9M | 4.45M | 2.29M |
| Change in cash | -3.24M | 3.57M | -4.76M | -8.92M | 12.1M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 18, 2026 | Current report | SEC |
| S-3 · Registration statement | Nov 17, 2026 | Offer document | SEC |
| 8-K · Current report | Nov 17, 2026 | Current report | SEC |
| 8-K/A · Current report, amended | Nov 10, 2026 | Material contract | SEC |
| RW · Request to withdraw a registration | Oct 9, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 29, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Sep 10, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 31, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 31, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 31, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| PRE 14A · Preliminary proxy statement | Aug 28, 2026 | Meeting notice | SEC |
| S-1 · Registration statement | Aug 21, 2026 | Offer document | SEC |
| 4/A · Change in ownership, amended | Aug 20, 2026 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Aug 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 5 · Annual statement of ownership | Aug 4, 2026 | Insider trade | SEC |
| 5 · Annual statement of ownership | Aug 4, 2026 | Insider trade | SEC |
| 5 · Annual statement of ownership | Aug 4, 2026 | Insider trade | SEC |
| 5 · Annual statement of ownership | Aug 4, 2026 | Insider trade | SEC |
| 5 · Annual statement of ownership | Aug 4, 2026 | Insider trade | SEC |
| 5 · Annual statement of ownership | Aug 4, 2026 | Insider trade | SEC |
| 5 · Annual statement of ownership | Aug 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 3, 2026 | Material contract | SEC |
| 10-K · Annual report | Jul 22, 2026 | Annual report | SEC |
| 8-K · Current report | Jul 21, 2026 | Current report | SEC |
| 8-K · Current report | Apr 17, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 20, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Mar 11, 2026 | Quarterly report | SEC |
| 424B5 · Prospectus | Mar 6, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 6, 2026 | Material contract | SEC |
| DEFA14A · Additional proxy material | Feb 26, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Feb 26, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Feb 9, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Dec 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 18, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 14, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 9, 2025 | Financing | SEC |
| 4 · Change in ownership | Oct 8, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 3, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 30, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 25, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 25, 2025 | Financing | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 19, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Sep 10, 2025 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 1, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 1, 2025 | Financing | SEC |
| 4 · Change in ownership | Aug 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 23, 2025 | Results | SEC |
| 10-K · Annual report | Jul 22, 2025 | Annual report | SEC |
| 144/A · Notice of proposed sale, amended | Jul 11, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 9, 2025 | Current report | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 9, 2025 | Other filings | SEC |
| 8-K · Current report | May 8, 2025 | Current report | SEC |
| 8-K · Current report | Apr 25, 2025 | Meeting outcome | SEC |
| 424B3 · Prospectus | Apr 9, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 9, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 4, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Mar 27, 2025 | Offer document | SEC |
| 4 · Change in ownership | Mar 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Mar 21, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Mar 19, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Mar 17, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 14, 2025 | Insider trade | SEC |
| DEF 14A · Proxy statement | Mar 13, 2025 | Meeting notice | SEC |
| S-3 · Registration statement | Mar 13, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Mar 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Mar 3, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Feb 28, 2025 | Meeting notice | SEC |
| 8-K · Current report | Feb 28, 2025 | Material contract | SEC |
| 8-K · Current report | Dec 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Dec 11, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 15, 2024 | Current report | SEC |
| 424B5 · Prospectus | Oct 3, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 3, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Sep 11, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 31, 2024 | Current report | SEC |
| 10-K · Annual report | Jul 30, 2024 | Annual report | SEC |
| NT 10-K · Late filing notice | Jul 30, 2024 | Explanation request | SEC |
| 8-K · Current report | Jul 12, 2024 | Current report | SEC |
| 424B3 · Prospectus | Jul 10, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 10, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 8, 2024 | Meeting outcome | SEC |
| CORRESP · Letter to the SEC | Jul 8, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jul 3, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 3, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 2, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 26, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 26, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 14, 2024 | Other filings | SEC |
| DEFA14A · Additional proxy material | Jun 11, 2024 | Meeting notice | SEC |
| S-1 · Registration statement | Jun 3, 2024 | Offer document | SEC |
| DEF 14A · Proxy statement | May 31, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 22, 2024 | Current report | SEC |
| 5 · Annual statement of ownership | May 16, 2024 | Insider trade | SEC |
| 8-K · Current report | May 15, 2024 | Current report | SEC |
| 8-K · Current report | May 13, 2024 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | May 10, 2024 | Meeting notice | SEC |
| 8-K/A · Current report, amended | May 10, 2024 | Material contract | SEC |
| 424B5 · Prospectus | May 10, 2024 | Offer document | SEC |
| 8-K · Current report | May 9, 2024 | Material contract | SEC |
| 8-K · Current report | May 9, 2024 | Current report | SEC |
| 424B5 · Prospectus | May 7, 2024 | Offer document | SEC |
| 8-K · Current report | May 7, 2024 | Current report | SEC |
| DEFA14A · Additional proxy material | May 1, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 1, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Apr 30, 2024 | Material contract | SEC |
| 4 · Change in ownership | Apr 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 29, 2024 | Material contract | SEC |
| 4 · Change in ownership | Mar 28, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Mar 25, 2024 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Mar 25, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 22, 2024 | Material contract | SEC |
| NT 10-Q · Late filing notice | Mar 18, 2024 | Explanation request | SEC |
| PRE 14A · Preliminary proxy statement | Mar 13, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 7, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 2, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 2, 2024 | Material contract | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 25, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 5, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Dec 27, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Dec 15, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2023 | Current report | SEC |
| 8-K · Current report | Oct 30, 2023 | Current report | SEC |
| 8-K · Current report | Sep 29, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Sep 26, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 22, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Sep 13, 2023 | Quarterly report | SEC |
| 424B5 · Prospectus | Sep 8, 2023 | Offer document | SEC |
| 8-K · Current report | Sep 8, 2023 | Material contract | SEC |
| DEFA14A · Additional proxy material | Sep 1, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Aug 24, 2023 | Meeting notice | SEC |
| 8-K · Current report | Aug 16, 2023 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Aug 11, 2023 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Aug 10, 2023 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Aug 8, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 8, 2023 | Other filings | SEC |
| 8-K · Current report | Aug 7, 2023 | Current report | SEC |
| S-3 · Registration statement | Aug 2, 2023 | Offer document | SEC |
| 10-K · Annual report | Jul 27, 2023 | Annual report | SEC |
| 8-K · Current report | Jun 22, 2023 | Current report | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2023 | Insider trade | SEC |
| 8-K · Current report | Apr 26, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Apr 25, 2023 | Current report | SEC |
| 8-K · Current report | Apr 3, 2023 | Current report | SEC |
| DEF 14A · Proxy statement | Mar 31, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 23, 2023 | Insider trade | SEC |
| 8-K · Current report | Mar 22, 2023 | Current report | SEC |
| 4 · Change in ownership | Mar 20, 2023 | Insider trade | SEC |
| 8-K · Current report | Mar 16, 2023 | Results | SEC |
| 10-Q · Quarterly report | Mar 15, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Feb 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2023 | Insider trade | SEC |
| 8-K · Current report | Feb 3, 2023 | Current report | SEC |
| 8-K · Current report | Jan 20, 2023 | Current report | SEC |
| 4 · Change in ownership | Dec 29, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Dec 12, 2022 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 30, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 30, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 30, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 30, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2022 | Insider trade | SEC |
| 8-K · Current report | Nov 16, 2022 | Current report | SEC |
| 4 · Change in ownership | Nov 15, 2022 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 15, 2022 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 3, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 1, 2022 | Insider trade | SEC |
| 8-K · Current report | Oct 31, 2022 | Current report | SEC |
| 4 · Change in ownership | Oct 14, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2022 | Insider trade | SEC |
This page holds 200 of 401 filings. Open Filings
Cap table
Built by 6ix from Alzamend Neuro, Inc.’s releases · as of Sep 10, 2026
- Common shares
- 4,825,723
- Fully diluted
- 4,825,723
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 4,825,723 | Sep 10, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 10, 2026 | 4,825,723 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Henry C.W. Nisser Other companies: Universal Safety Products, Inc. (Director · Since at least Oct 20, 2025); Hyperscale Data, Inc. (General Counsel · Since at least May 1, 2019); Algorhythm Holdings, Inc. (Director · Apr 5, 2023 – Aug 2, 2024 · Past); TurnOnGreen, Inc (Chief Executive Officer, Director · Dec 16, 2021 – Dec 16, 2021 · Past); Ault Disruptive Technologies Corp (President and General Counsel, Director · Dec 15, 2021 – Dec 15, 2021 · Past) | Executive Vice President, General Counsel and Director · Since at least Jun 14, 2021 |
| Milton C Ault III Other companies: Universal Safety Products, Inc. (Director · Since at least Jul 29, 2025); Hyperscale Data, Inc. (Executive Chairman, Director · Since at least Oct 20, 2023); Ault Disruptive Technologies Corp (Director · Sep 30, 2024 – Sep 30, 2024 · Past); RiskOn International, Inc. (Chief Executive Officer, Director · Jan 23, 2024 – Apr 24, 2024 · Past) | Director · Since at least Jan 5, 2024 |
| David J. Katzoff Other companies: TurnOnGreen, Inc (CFO, Secretary, Treasurer · Dec 16, 2021 – Jun 26, 2023 · Past); Ault Disruptive Technologies Corp (Vice President - Finance · Dec 15, 2021 – Dec 15, 2021 · Past) | Chief Financial Officer · Since at least Jun 14, 2021 |
| Mark Gustafson C.P.A. Other companies: Ault Disruptive Technologies Corp (Director · Dec 15, 2021 – Dec 15, 2021 · Past); Triangle Petroleum Corporation (Chief Executive Officer, Director · Jan 16, 2007 – Oct 30, 2009 · Past) | Chief Financial Officer of PharmaKure Limited · Since at least Jun 14, 2021 |
| Kenneth S. Cragun Other companies: Hyperscale Data, Inc. (Chief Financial Officer · Since at least Sep 4, 2026) | Senior Vice President of Finance · Since at least Nov 5, 2026 |
| William B. Horne Other companies: Hyperscale Data, Inc. (Chief Executive Officer, Director · Since at least Dec 30, 2024) | Director · Since at least Mar 18, 2025 |
| Andrew H Woo | Director · Jun 14, 2021 – Mar 15, 2022 · Past |
| Escalona Lien | Chief Financial Officer · Jun 14, 2021 – Jun 14, 2021 · Past |
| Jeffrey Oram | Director · Since at least Jun 14, 2021 |
| Lynne Fahey McGrath | Director · Since at least Jun 14, 2021 |
All 12 people
| Person | Seat |
|---|---|
| Milton C Ault | Founder and Vice Chairman of Alzamend · Since at least Aug 4, 2026 |
| Stephan Jackman | Chief Executive Officer and Director · Since at least Jun 14, 2021 |
Log in to ask 6ix AI your own questions about Alzamend Neuro, Inc.